Date de publication: 13 janvier 2005
Promoteur – Intermédiaire Financier
Orion CorporationLieu
Description
The project comprises numerous initiatives for discovery and production of pharmaceuticals in selected core therapeutic areas (central nervous system, cardiovascular diseases and hormonal therapies).
Objectifs
The Project would support the company’s RDI expenditure aimed at producing proprietary original pharmaceutical innovations. It corresponds to EU policy and the objectives of the Bank’s Innovation 2010 Initiative to bolster investments in human capital, and industrial innovation and research.
Commentaires
i2i – Research, development and innovative investments (RDI), as well as creation and diffusion of new technologies.
Secteur(s)
Montant BEI envisagé (montant approximatif)
Loan of up to EUR 150 million
Coût total (montant approximatif)
EUR 300 million
Aspects environnementaux
The expected increase in R&D activities will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11/EC.
Passation des marchés
The promoter, as a private company is not bound by EU Directives on procurement. R&D activities are generally carried out by the promoter research staff. Procedures for procuring specialized equipment and external services will be varified during appraisal.
Statut
Signé - 15/12/2006